Leigh MacConell

7.4k total citations · 1 hit paper
80 papers, 4.1k citations indexed

About

Leigh MacConell is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Leigh MacConell has authored 80 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Epidemiology, 36 papers in Hepatology and 34 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Leigh MacConell's work include Liver Disease Diagnosis and Treatment (33 papers), Liver Diseases and Immunity (30 papers) and Diabetes Treatment and Management (24 papers). Leigh MacConell is often cited by papers focused on Liver Disease Diagnosis and Treatment (33 papers), Liver Diseases and Immunity (30 papers) and Diabetes Treatment and Management (24 papers). Leigh MacConell collaborates with scholars based in United States, United Kingdom and Netherlands. Leigh MacConell's co-authors include Michael Trautmann, Ted Okerson, Wylie Vale, Ezra Wiater, Ping Yan, Louise M. Bilezikjian, Peter C. Gray, Carol Wysham, Kathleen Lewis and Amy L. Blount and has published in prestigious journals such as Nature, The Lancet and Gastroenterology.

In The Last Decade

Leigh MacConell

77 papers receiving 4.0k citations

Hit Papers

Efficacy and safety of exenatide once weekly versus sitag... 2010 2026 2015 2020 2010 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
    2010 510 citations Richard M. Bergenstal, Carol Wysham et al. profile →

Peers

Leigh MacConell
Junji Ishida Japan
Hideichi Makino Japan
Conor Woods Ireland
Anna Gumà Spain
Hiroto Furuta Japan
Martin Hennenberg Germany
Xiemin Cao Canada
Silvia Heringer‐Walther Germany
Kentaro Yamada Japan
Stanley C. Rall United States
Junji Ishida Japan
Leigh MacConell
Citations per year, relative to Leigh MacConell Leigh MacConell (= 1×) peers Junji Ishida

Countries citing papers authored by Leigh MacConell

Since Specialization
Citations

This map shows the geographic impact of Leigh MacConell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leigh MacConell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leigh MacConell more than expected).

Fields of papers citing papers by Leigh MacConell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leigh MacConell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leigh MacConell. The network helps show where Leigh MacConell may publish in the future.

Co-authorship network of co-authors of Leigh MacConell

This figure shows the co-authorship network connecting the top 25 collaborators of Leigh MacConell. A scholar is included among the top collaborators of Leigh MacConell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leigh MacConell. Leigh MacConell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shah, Amrik, Leigh MacConell, A. Sender Liberman, Adrian M. Di Bisceglie, & Д. А. Шапиро. (2025). Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical Modelling. Alimentary Pharmacology & Therapeutics. 61(9). 1489–1499. 1 indexed citations
2.
Alkhouri, Naim, Jeffrey E. Edwards, Fred Poordad, et al.. (2024). Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH. Liver International. 44(4). 966–978. 10 indexed citations
3.
Carr, Rotonya M., Yun Li, Lillian Chau, et al.. (2023). An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations. Hepatology. 78(6). 1843–1857. 16 indexed citations
4.
Hirschfield, Gideon M., Florencia Carbone, Christopher L. Bowlus, et al.. (2021). A43 LONG-TERM EFFICACY AND SAFETY OF OBETICHOCLIC ACID IN PRIMARY BILIARY CHOLANGITIS: RESPONDER ANALYSIS OF OVER 5 YEARS OF TREATMENT IN THE POISE TRIAL. Journal of the Canadian Association of Gastroenterology. 4(Supplement_1). 229–231.
5.
Hirschfield, Gideon M., Marco Carbone, David Jones, et al.. (2021). O24 Durability of obeticholic acid response in PBC patients who did not achieve poise trial criteria. INFM-OAR (INFN Catania). A13.1–A13. 1 indexed citations
6.
Kowdley, Kris V., Raj Vuppalanchi, Cynthia Levy, et al.. (2020). A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Journal of Hepatology. 73(1). 94–101. 142 indexed citations
7.
Harms, Maren H., Gideon M. Hirschfield, Annarosa Floreani, et al.. (2020). Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. JHEP Reports. 3(1). 100191–100191. 11 indexed citations
8.
Trauner, Michael, Frederik Nevens, Mitchell L. Shiffman, et al.. (2019). Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. ˜The œLancet. Gastroenterology & hepatology. 4(6). 445–453. 124 indexed citations
9.
Hirschfield, Gideon M., Annarosa Floreani, Richard Pencek, et al.. (2017). PTU-097 Long-term effect of obeticholic acid on transient elastography and ast to platelet ratio index in patients with pbc. Gut. 66. A98.3–A99. 1 indexed citations
10.
11.
Wysham, Carol, Leigh MacConell, David Maggs, et al.. (2015). Five-Year Efficacy and Safety Data of Exenatide Once Weekly. Mayo Clinic Proceedings. 90(3). 356–365. 47 indexed citations
12.
Parés, Albert, Richard Pencek, Yonne Peters, et al.. (2015). P1155 : FXR Agonism with obeticholic acid may attenuate bone mineral density decrease in subjects with primary biliary cirrhosis. Journal of Hepatology. 62. S786–S786. 3 indexed citations
13.
MacConell, Leigh, et al.. (2015). Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metabolic Syndrome and Obesity. 8. 241–241. 36 indexed citations
14.
Rosenstock, Julio, Sylvia Shenouda, Richard M. Bergenstal, et al.. (2012). Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes. Diabetes Care. 35(5). 955–958. 59 indexed citations
15.
Ridge, Terry, Leigh MacConell, Richard Pencek, et al.. (2012). Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP ‐1 receptor agonism in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 14(12). 1097–1103. 28 indexed citations
16.
17.
18.
DeYoung, Mary Beth, et al.. (2011). Encapsulation of Exenatide in Poly-( d,l -Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes. Diabetes Technology & Therapeutics. 13(11). 1145–1154. 204 indexed citations
19.
Fineman, Mark, Shawn Flanagan, Kristin Taylor, et al.. (2010). Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing. Clinical Pharmacokinetics. 50(1). 65–74. 117 indexed citations
20.
Takabe, Kazuaki, Lili Wang, A.M.O. Leal, et al.. (2003). Adenovirus–Mediated Overexpression of Follistatin Enlarges Intact Liver of Adult Rats. Hepatology. 38(5). 1107–1115. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Junji Ishida Breakdown of academic impact, for papers by Hideichi Makino Breakdown of academic impact, for papers by Conor Woods Breakdown of academic impact, for papers by Anna Gumà Breakdown of academic impact, for papers by Hiroto Furuta Breakdown of academic impact, for papers by Martin Hennenberg Breakdown of academic impact, for papers by Xiemin Cao Breakdown of academic impact, for papers by Silvia Heringer‐Walther Breakdown of academic impact, for papers by Kentaro Yamada Breakdown of academic impact, for papers by Stanley C. Rall
Rankless by CCL
2026